Last reviewed · How we verify
NCT04386993: DeCRESCEndo
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NA trial testing Intensity modulated radiation therapy in Endometrial Cancer in 25 participants. Completed in 13 October 2025.
13 October 2025
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 7 July 2020 |
| Primary completion | 13 October 2025 |
| Estimated completion | 13 October 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intensity modulated radiation therapy
Conditions studied
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
Washington University School of Medicine
Who can join
18 and older, any sex, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage III-IVA endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology. The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate \< 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Determinants of Sensitivity to Radiotherapy in Endometrial Cancer.
Sorolla MA, Parisi E, Sorolla A. · · 2020 · cited 22× · PMID 32679719 · DOI 10.3390/cancers12071906
Verify or expand the search:
- PubMed search for NCT04386993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intensity modulated radiation therapy
Trials testing the same drug.
- NCT03910634 — IMRT With Carboplatin Versus IMRT With Carboplatin and Fluorouracil for Eldly Esophageal Cancer Patients · Phase 2 · unknown
- NCT03621696 — Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "T · Phase 2 · active not recruiting
- NCT03300765 — Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer · Phase 2 · unknown
- NCT02296684 — Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · completed
- NCT01908478 — Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer · Phase 1 · completed
Other recruiting trials for Endometrial Cancer
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04386993 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04386993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing